
Finerenone significantly improves cardiovascular outcomes in patients with diabetes, chronic kidney disease, and heart failure. The meta-analysis of 8 trials with 21,200 patients found finerenone reduced all-cause death (RR 0.92) and major cardiovascular events (RR 0.85). Heart failure hospitalizations were also reduced (RR 0.82), although CV death showed a trend without significance (RR 0.90). Hyperkalemia was more common (RR 2.07), but adverse events remained similar.
Like
Save
Share